Actively Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy
Led by Beijing Tiantan Hospital · Updated on 2026-02-10
568
Participants Needed
6
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of perfusion-guided endovascular treatment (EVT) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 24 hours from symptom onset.
CONDITIONS
Official Title
Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Acute ischemic stroke symptom onset within 24 hours, including wake-up or unwitnessed stroke (time refers to last-seen normal time)
- Primary medium vessel occlusion confirmed by CTA/MRA in specified brain artery segments causing stroke symptoms
- Pre-stroke modified Rankin Scale (mRS) score of 1 or less
- Baseline National Institutes of Health Stroke Scale (NIHSS) score of 8 or higher
- Target mismatch profile on CT perfusion or MRI+MR perfusion (ischemic core volume less than 70 mL, mismatch ratio greater than 1.2, mismatch volume greater than 10 mL)
- Written informed consent from patient or legally authorized representative
You will not qualify if you...
- Any evidence of intracranial hemorrhage on qualifying imaging
- Known serious sensitivity to radiographic contrast agents, nickel, titanium metals, or their alloys preventing completion of required imaging
- History of arterial tortuosity, pre-existing stent, arterial disease, or access site disease preventing safe EVT
- Radiological evidence of mass effect or intracranial tumor (except small meningioma)
- Clinical diagnosis of cerebral vasculitis
- Evidence of vessel recanalization before randomization
- Severe comorbidities likely to prevent improvement or follow-up
- Terminal illness with expected survival less than 1 year
- Hypodensity in more than one-third of the MCA territory on non-contrast CT or significant hypodensity outside current perfusion lesion
- Multiple arterial occlusions
- Pregnant or nursing women, or unwillingness to use effective contraception during the trial
- Unlikely to adhere to trial protocol or follow-up
- Participation in other interventional clinical trials within the previous 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Beijing tiantan hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
2
Beijing Daxing District People's Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
3
Xingtang County People's Hospital
Longzhou, Hebei, China
Actively Recruiting
4
Luoyang Yiluo Hospital
Luoyang, Henan, China
Actively Recruiting
5
People's Hospital of Queshan
Panlong, Henan, China
Actively Recruiting
6
Changle People's Hospital
Changle, Shandong, China
Actively Recruiting
Research Team
Y
Yunyun Xiong, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here